ANDA 89143, held by Abraxis Pharmaceuticals. Methylprednisolone Sodium Succinate.
As of Nov 21, 2026, ANDA 89143 (Methylprednisolone Sodium Succinate), held by Abraxis Pharmaceuticals, was first approved by FDA on Mar 28, 1986, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 28, 1986 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Methylprednisolone Sodium SuccinateEQ 40MG BASE/VIAL · injectable;injection | Methylprednisolone Sodium Succinate | Discontinued |
| Oct 26, 1989 | Supplement 4Labeling | Approved | None posted |
| Mar 28, 1986 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters